In the current study, AbMAs developed previously [30,38], were used to measure the changes in CST4, S100A6 and MMP9 protein in the tears of patients with SS to assess if these biomarkers might serve to test the ocular involvement and active inflammation in this disease, and naturally, if they could be used to monitor the response to therapy. This evidence concerns the gene MMP9 and synovial sarcoma.